It’s been more than 35 years since Peter Kahan and Dr. Ravi Munver first met. Back then, they were a teacher and his student, respectively. These days, the two men remain connected, but their relationship has evolved — Munver is now a key member of Kahan’s bladder cancer care team.
“To have to have a somebody who really looks upon you as a friend as (your) doctor, (who) really can see you as more than just another patient is great,” said Kahan, who described his connection with Munver, a urologic oncologist and vice chair of the department of urology at Hackensack University Medical Center in New Jersey, as “completely” crucial to his cancer journey.
“You know, there are a lot of physicians who are phenomenal,” said Munver. “But when you meet them, to them you’re a patient, and they care for you as a patient. It’s very different when you either have a personal relationship with a physician, or you have a physician who literally has a motto that says ‘I treat all of my patients like my friends and family,’ meaning if Peter walked in the door or a family friend walked in the door or a distant family member walked in the door, I would treat them all exactly the same. One would not get more time or better treatment than another. So, when you have physicians that have that model where they treat every patient as if they were their own family member or friend, you just get a different feel flavor and level of care.”
Peter Kahan and his oncologist and former student, Dr. Ravi Munver.
Photo courtesy Hackensack University Medical Center
Kahan was Munver’s honors physics teacher at the Dwight-Englewood school in northern New Jersey in 1987, where he noted that Munver was “one of my best students. … He was extremely meticulous and careful in his work.”
“Of all the sciences that I took — biology, chemistry, physics — physics really came easy to me, because it was math-based,” Munver said. “And I just remember obviously trying to do well in the class, but also enjoying the material. You have a great teacher, a teacher who teaches the material, who loves the material and has a passion for it, it makes that class that much easier and more fun and enjoyable, especially when you’re first semester senior applying to college. And once I’d gotten into college, obviously, it was just a continuation of just more fun and learning. So, I really enjoyed class and I think what I remember most about it was it was a topic that was easy for me but enjoyable and very different from all of the other natural sciences.”
The two men re-connected years later at a memorial service for a former teacher at Dwight-Englewood. Kahan, retired from teaching and living in upstate New York, discovered blood in his urine in 2019, and he subsequently received a diagnosis of high-grade non-muscle invasive bladder cancer from his local urologist.
Treatment with the immunotherapy bacillus calmette-guerin (BCG) and the chemotherapy mitomycin inserted directly into the bladder followed. When his cancer recurred, Munver’s doctors recommended he seek a cystectomy, or removal of the bladder and prostate, at Memorial Sloan-Kettering Cancer Center in New York City.
Kahan reached out to Munver, looking for a second opinion.
“As director of minimally invasive and robotic urologic surgery, I’m always looking at novel techniques, novel therapies that can offer patients good results, as well as a great quality of life,” said Munver. “And when Peter had told me about the traditional therapies that were being used, we use them as well. We use BCG. … When BCG fails, many urologists will jump to the next step, which is removal of the bladder. And that’s what I learned in residency 22 years ago, and that’s what people learned 30 years ago, and that’s what people learned 50 years ago, it was that was the only algorithm.
“However, a lot has changed, and I wanted to make sure that if he needed his bladder out, that (that) was the right thing to do. And it didn’t have to be (done by) with me with robotic surgery, it could have been at any other institution of his choice. But at least I wanted to offer him a second opinion from someone who is in the academic space and knows all of the latest therapies out there.”
Munver surgically removed the tumor and treated him with the immunotherapy combination of BCG and interferon. When the tumor returned, Hackensack had received approval for the novel chemotherapy drug combination of gemcitabine and docetaxel, administered in liquid form directly into the bladder.
“In combination, the two medicines would really have a cancer cell destroying effect, and the clinical trials have been going on for years but we weren’t able to accrue enough patients across the country and across the world to really see a demonstrable effect, we needed at least several year(s’ of) data to be able to say, ‘Yes, this works compared to our traditional therapies,’” Munver said.
“It’s a massive undertaking to bring a new therapy to our patients, and we’d been working on it for months,” Dr. Nitin Yerram, director of urologic research at Hackensack, said in a statement. “Right when we were about to go live, Peter was looking for options.”
Studies have shown that up to half of patients respond to this novel therapy and are able to avoid surgery, Yerram said.
Kahan began treatment with the chemotherapy combination in January 2022, and he tells CURE® it has been approximately a year and a half since any tumors were found, through florescence in situ hybridization (FISH) tests, which check for chromosomal multiplications, have come back positive. “It’s not necessarily that there are cancer cells, but there are cells that have a tendency to increase their proliferation. And we often see those in cancer cells,” Munver said.
“We have several patients who are on this therapy right now, and several of the patients do have a positive urine test, but there’s visibly no evidence of tumor I can see,” said Munver. “And I can see tumors as small as one to two millimeters. … As I mentioned to Peter, if the tumors return, basically the bladder cancer will declare itself and to this point, it is not, and we are just monitoring him very closely. And you know, we cross our fingers and hope that this therapy keeps him with a really good quality of life for many years to come.”
In this episode of the “Cancer Horizons” podcast, Kahan and Munver speak with CURE about the importance of their friendship and their decision to embrace a new treatment option.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
